| abstract |
[6R]-5,10-Methylene-tetrahydrofolate for use in the treatment of solid tumors, including cancer, in a human, which treatment comprises the following steps: a) on day 1, administering an i.v. containing 10-1000 mg/m2 (of ASC) of a fluorinated pyrimidine base such as 5-fluorouracil (5-FU), followed either simultaneously or after a period of 10 min - 4 hours, by b) administer two or more iv boluses, 10 - 60 minutes apart, each containing 5 - 1000 mg/m2 of [6R]-5,10-methylenetetrahydrofolate, followed by c) administer a continuous infusion of a fluorinated pyrimidine base such as 5-FU over a 46 hour period, or until the end of day 2, followed by d) optionally administering an iv bolus containing 5 - 1000 mg/m2 (of BSA) of [6R]-5,10-methylene-tetrahydrofolate before the end of day 1, followed by e) on day 2, optionally administer one or more i.v. each containing 5-1000 mg/m2 (ASC) of [6R]-5,10-methylene-tetrahydrofolate, wherein step b) is optionally repeated up to 4 times on day 1 with an interval of 10 min - 4 hours between each repetition, and in which step e) is optionally repeated up to 4 times on day 2 with an interval of between 10 min - 60 min between each bolus that is administered, and in which all the steps a) - e) are optionally repeated every 2 weeks for up to eight (8) cycles, ie up to sixteen (16) weeks. |